Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant

The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.